Last updated on April 2018

Study of a new medication for the treatment of Alzheimer's Disease

Brief description of study

This is a Phase I study to assess a new medication in patients with Alzheimer's Disease and periodontitis (gum disease).  Qualified participants will receive at no charge, study related physical exams, EKGs, lab work and study medication.  

Detailed Study Description

The objective of this study is to assess the safety and tolerability of the study drug given orally twice daily for 28 days. The study will also assess the effects of study drug on oral and cerebrospinal fluid biomarkers. The study evaluations include 2 detailed dental examinations and 2 lumbar punctures. The efficacy of the study drug in Alzheimer's disease has not been tested yet.

Clinical Study Identifier: TX203031

Find a site near you

Start Over

Bioclinica Research

100 West Gore Street, Suite 501B Orlando, FL United States
  Connect »

Pacific Research Network, Inc.

16766 Bernardo Center Dr., Suite 102 San Diego, CA United States
  Connect »